Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis - a nationwide cohort study
Alimentary Pharmacology and Therapeutics, 05/10/2012Norgard BM et al.
Based on nationwide data on ulcerative colitis (UC) patients having colectomies, pre–operative use of anti–TNF–α agents did not increase the risk of post–operative complications.
Based on the Danish National Patient Registry the authors identified all UC patients, aged ≥15 years, having their first surgery for UC in the period of 1 January 2003-31 December 2010 (n = 1226).
Patients were classified according to use of anti-TNF-α agents within 12 weeks before surgery or not.
Outcome data were obtained from Danish registries.
Logistic regression analyses were used to estimate adjusted risks [with 95% confidence intervals (CI)] of post-operative outcomes among patients treated with anti-TNF-α agents, relative to those not treated.
A total of 199 UC patients were exposed to anti-TNF-α agents within 12 weeks before colectomy, and 1027 were not.
Among exposed, the adjusted odds ratio of reoperation and anastomosis leakage within 30 days after colectomy was 1.07 (95% CI: 0.71-1.59) and 0.52 (95% CI: 0.06-4.11) respectively.
No deaths, cases of abscess drainage or bacteremia occurred among exposed within 30 days.
Furthermore, no increased relative risks were found within 60 days after colectomy.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.